What changed: label update log
33 ENTRIES · NEWEST FIRST
Reviewed by Tariq Halim, MD · Last medical review: November 12, 2026 · Editorial policy
Method: label revision dates and Recent Major Changes come from the DailyMed pages read on Oct 29, 2026. When a label was revised but lists no Recent Major Changes, the entry says the specific edits were not identified; no change is inferred. Entries marked “marketing end dates, not a label revision” report the marketing end dates shown in DailyMed product listings (retrieved Oct 29, 2026); they do not mean the label text changed.
Changes
Oct 30, 2026
Simtriyo (centanafadine) placed in DEA Schedule III; now marketable
The DEA published an interim final rule placing centanafadine in Schedule III (CIII), effective the same day: 91 FR 68470, FR Doc. 2026-22208, Docket No. DEA-1743. Public comments are due Nov 30, 2026.
FDA approval of Simtriyo became effective when the rule was published, so Simtriyo can now be marketed. The Prescribing Information revised 10/2026 is labeled CIII. DailyMed (SPL version 1, published Oct 26, 2026) lists a marketing start date of Oct 24, 2026.
No Otsuka launch press release was found and pharmacy stocking was not confirmed as of Nov 4, 2026: check pharmacy availability. There is no generic or authorized generic.
Page: Simtriyo · Source: Federal Register: 91 FR 68470 · Simtriyo Prescribing Information, revised 10/2026 · DailyMed: Simtriyo
Oct 29, 2026 (DailyMed listing checked; marketing end dates, not a label revision)
Ritalin LA (brand): marketing end dates listed on DailyMed
DailyMed’s listing for brand Ritalin LA (Novartis; SPL version 36) shows marketing end dates of Sep 30, 2026 for the 10 mg and 30 mg capsules and Oct 31, 2026 for the 20 mg and 40 mg capsules. These are marketing dates in the product listing, not a change to the label, which is still revised 9/2025.
The Sandoz authorized-generic listing shows its capsules as marketed with no end date. The FDA Orange Book still lists the 10 to 40 mg brand strengths as active (rechecked Oct 29, 2026).
Page: Ritalin LA · Source: DailyMed SPL: Ritalin LA (Novartis), version 36, retrieved Oct 29, 2026 · DailyMed SPL: Sandoz authorized generic, retrieved Oct 29, 2026
Oct 29, 2026 (DailyMed listing checked; marketing end dates, not a label revision)
Mylan generic methylphenidate patch: marketing end dates listed on DailyMed
DailyMed’s listing for Mylan’s generic methylphenidate transdermal system (SPL version 6) shows marketing end dates of Jan 31, 2027 for the 30 mg patch and Apr 30, 2027 for the 10, 15 and 20 mg patches. These are marketing dates in the product listing, not a change to the label.
As of Oct 29, 2026, ASHP lists Mylan (Viatris) patches as available, and the Padagis authorized-generic listing shows no end date.
Page: Daytrana · Source: DailyMed SPL: Mylan methylphenidate transdermal system, version 6, retrieved Oct 29, 2026 · DailyMed SPL: Padagis authorized generic, retrieved Oct 29, 2026
Oct 29, 2026 (DailyMed listing checked; marketing end dates, not a label revision)
Aptensio XR: marketing end date listed on DailyMed; listing dropped from DailyMed search
DailyMed’s listing for brand Aptensio XR (Rhodes; SPL version 17, published May 25, 2026) shows a marketing end date of May 20, 2026 for all seven strengths. This is a marketing date in the product listing, not a change to the label.
On Oct 29, 2026 the listing no longer appeared in DailyMed search results, although its page still opened from a direct link. The FDA Orange Book still lists all seven strengths as active, and ASHP lists the brand and the Rhodes authorized generic on back order.
Page: Aptensio XR · Source: DailyMed SPL: Aptensio XR (Rhodes), version 17, retrieved Oct 29, 2026 · DailyMed search for Aptensio (no results), Oct 29, 2026
Oct 26, 2026
Simtriyo label posted on DailyMed (before DEA scheduling)
DailyMed posted the Simtriyo (centanafadine) label; that version stated that the controlled-substance schedule was pending (the label revised 10/2026 is labeled CIII).
The DEA rule to place centanafadine in Schedule III finished federal (OIRA) review on Oct 22, 2026; it was published on Oct 30, 2026 (see that entry), which made the FDA approval effective.
Page: Simtriyo · Source: DailyMed: Simtriyo · reginfo.gov: OIRA review RIN 1117-ZA11 · Federal Register search: centanafadine
Oct 2026 (label revised 10/2026; DailyMed SPL date Oct 21, 2026)
Metadate CD label revised (Lannett)
Indication is now pediatric patients 6 years and older (previously ages 6 to 15); the label is not indicated for adults.
Alcohol is now listed as a drug interaction (section 7); the Medication Guide’s most common side effects add headache and stomach pain; contraindications are listed in full (Recent Major Changes: Contraindications, 07/2026).
Page: Metadate CD · Source: Metadate CD label (revised 10/2026)
Jul 24, 2026
Simtriyo (centanafadine) approved by FDA
FDA approved Simtriyo (NDA 218145, Otsuka) for ADHD in adults and in children 6 and older who weigh at least 20 kg; label dated 07/2026. Marketing had to wait for DEA scheduling, which took effect Oct 30, 2026 (see that entry).
Page: Simtriyo · Source: FDA approval letter
Jun 2026 (label revised 6/2026; DailyMed SPL date Jun 30, 2026)
Strattera label revised
The label was revised 6/2026 but lists no Recent Major Changes, so the specific edits were not identified for this log.
Page: Strattera (atomoxetine) · Source: Strattera (atomoxetine) label (revised 06/2026)
Apr 2026 (label revised 4/2026; DailyMed SPL date Apr 20, 2026)
Concerta label revised
Dosage sections 2.3 (patients new to methylphenidate) and 2.4 (patients switching from another methylphenidate product) changed in 2/2026.
The warnings on seizures and on periodic hematologic (blood count) monitoring were removed in 2/2026.
Also listed as recent: the 9/2025 Indications change (not recommended under age 6) and the long-term growth suppression warning.
Page: Concerta · Source: Concerta label (revised 04/2026)
April 2026
Vyvanse label revised
Current label revised 4/2026 (DailyMed SPL date April 30, 2026).
Recent Major Changes listed on the label: Indications and Usage (1), 09/2025; Warnings and Precautions (5.5 Long-Term Suppression of Growth in Pediatric Patients), 09/2025.
Page: Vyvanse · Source: Vyvanse label (revised 04/2026)
April 2026
QuilliChew ER label revised
Current label revised 4/2026 (DailyMed SPL date April 8, 2026).
Recent Major Changes listed on the label: Indications and Usage (1), 09/2025; Warnings and Precautions (5.7 Long-Term Suppression of Growth in Pediatric Patients), 09/2025; Dosage Forms and Strengths (3), 03/2026.
Page: QuilliChew ER · Source: QuilliChew ER label (revised 04/2026)
April 2026
Mydayis label revised
Current label revised 4/2026 (DailyMed SPL date April 30, 2026).
The label lists no Recent Major Changes, so the specific edits were not identified for this log.
Page: Mydayis · Source: Mydayis label (revised 04/2026)
April 2026
Adderall XR label revised
Current label revised 4/2026 (DailyMed SPL date April 30, 2026).
Recent Major Changes listed on the label: Indications and Usage (1), 09/2025; Warnings and Precautions (5.5 Long-Term Suppression of Growth in Pediatric Patients), 09/2025.
Page: Adderall XR · Source: Adderall XR label (revised 04/2026)
Mar 20, 2026
Atoncy (atomoxetine oral solution) approved; marketing started
FDA approved Atoncy, a 4 mg/mL atomoxetine oral solution (NDA 220320), on Mar 20, 2026; DailyMed lists Atoncy and an authorized generic with a marketing start of Mar 20, 2026. Current label revised 3/2026 (first DailyMed version effective Apr 2, 2026).
Page: Atoncy · Source: Atoncy label (SPL version 1, effective Apr 2, 2026)
Mar 20, 2026
Arynta marketing started
DailyMed lists a marketing start date of Mar 20, 2026 for Arynta (approved Jun 16, 2025, NDA 219847).
Page: Arynta · Source: FDA approval letter · Arynta label (revised 12/2025)
March 2026
Quillivant XR label revised
Current label revised 3/2026 (DailyMed SPL date March 24, 2026).
Recent Major Changes listed on the label: Dosage Forms and Strengths (3), 03/2026; Indications and Usage (1), 09/2025; Warnings and Precautions (5.7 Long-Term Suppression of Growth in Pediatric Patients), 09/2025.
Page: Quillivant XR · Source: Quillivant XR label (revised 03/2026)
Dec 31, 2025
DEA and HHS extend telemedicine prescribing of controlled medicines through 2026
The DEA, jointly with HHS, published a fourth temporary extension of the COVID-19 telemedicine flexibilities for prescribing controlled medications (90 FR 61301, FR Doc. 2025-24123). It is effective Jan 1, 2026 through Dec 31, 2026.
The flexibilities let practitioners prescribe Schedule II–V controlled medications, which include ADHD stimulants, through audio-video telemedicine visits without the in-person evaluation the Ryan Haight Act otherwise requires, provided the prescriptions meet the other requirements. No further extension had been published in the Federal Register as of Nov 9, 2026.
Pages: Concerta, Focalin XR, Jornay PM, Ritalin LA, Aptensio XR, Quillivant XR, Cotempla XR-ODT, Azstarys, Daytrana, Ritalin, Adhansia XR, QuilliChew ER, Focalin, Relexxii, Metadate CD, Methylin, Methylphenidate ER (10/20 mg), Methylphenidate Chewable, Vyvanse, Adderall XR, Xelstrym, Adderall, Mydayis, Adzenys XR-ODT, Dyanavel XR, Evekeo, Arynta, Zenzedi, ProCentra, Dexedrine Spansule, Evekeo ODT, Desoxyn, Simtriyo · Source: Federal Register: 90 FR 61301
December 2025
Arynta label revised
Current label revised 12/2025 (DailyMed SPL date July 30, 2025).
DailyMed’s SPL effective date is earlier than the revision date printed on the label; both are shown as published.
Recent Major Changes listed on the label: Indications and Usage (1), 09/2025; Warnings and Precautions (5.5 Long-Term Suppression of Growth in Pediatric Patients), 09/2025.
Page: Arynta · Source: Arynta label (revised 12/2025)
October 2025
Methylphenidate ER (10/20 mg) label revised
Current label revised 10/2025 (DailyMed SPL date October 8, 2025).
The label lists no Recent Major Changes, so the specific edits were not identified for this log.
Page: Methylphenidate ER (10/20 mg) · Source: Methylphenidate ER (10/20 mg) label (revised 10/2025)
October 2025
Kapvay label revised
Current label revised 10/2025 (DailyMed SPL date October 31, 2025).
The label lists no Recent Major Changes, so the specific edits were not identified for this log.
Page: Kapvay · Source: Kapvay label (revised 10/2025)
Sep 2025
Stimulant labels: use under age 6 not recommended; growth warning revised
These labels list two Recent Major Changes dated 09/2025: Indications and Usage (section 1) now states that use is not recommended in children younger than 6 because they had higher drug exposure and more side effects (such as weight loss) at the same dose, and the Long-Term Suppression of Growth in Pediatric Patients warning was revised.
Pages: Adderall XR, Adzenys XR-ODT, Aptensio XR, Arynta, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Dyanavel XR, Focalin XR, Jornay PM, QuilliChew ER, Quillivant XR, Relexxii, Ritalin LA, Vyvanse, Xelstrym · Source: each product’s label: see Current label versions below
June 2025
Intuniv label revised
Current label revised 6/2025 (DailyMed SPL date June 23, 2025).
The label lists no Recent Major Changes, so the specific edits were not identified for this log.
Page: Intuniv · Source: Intuniv label (revised 06/2025)
June 2025
Evekeo label revised
Current label revised 06/2025 (DailyMed SPL date October 10, 2025).
The label lists no Recent Major Changes, so the specific edits were not identified for this log.
Page: Evekeo · Source: Evekeo label (revised 06/2025)
May 2025
Zenzedi label revised
Current label revised 05/2025 (DailyMed SPL date November 26, 2025).
The label lists no Recent Major Changes, so the specific edits were not identified for this log.
Page: Zenzedi · Source: Zenzedi label (revised 05/2025)
May 2025
ProCentra label revised
Current label revised 05/2025 (DailyMed SPL date May 14, 2025).
The label lists no Recent Major Changes, so the specific edits were not identified for this log.
Page: ProCentra · Source: ProCentra label (revised 05/2025)
April 2025
Onyda XR label revised
Current label revised 4/2025 (DailyMed SPL date April 11, 2025).
Recent Major Changes listed on the label: Warnings and Precautions (5.3 Rebound Hypertension), 04/2025.
Page: Onyda XR · Source: Onyda XR label (revised 04/2025)
March 2025
Methylphenidate Chewable label revised
Current label revised 3/2025 (DailyMed SPL date March 12, 2025).
The label lists no Recent Major Changes, so the specific edits were not identified for this log.
Page: Methylphenidate Chewable · Source: Methylphenidate Chewable label (revised 03/2025)
February 2025
Ritalin label revised
Current label revised 2/2025 (DailyMed SPL date February 5, 2025).
The label lists no Recent Major Changes, so the specific edits were not identified for this log.
Page: Ritalin · Source: Ritalin label (revised 02/2025)
January 2025
Qelbree label revised
Current label revised 1/2025 (DailyMed SPL date October 5, 2026).
The label lists no Recent Major Changes, so the specific edits were not identified for this log.
Page: Qelbree · Source: Qelbree label (revised 01/2025)
September 2024
Desoxyn label revised
Current label revised 9/2024 (DailyMed SPL date September 30, 2024).
Recent Major Changes listed on the label: Boxed Warning, 10/2023; Dosage and Administration (2.1 Pretreatment Screening), 10/2023; Warnings and Precautions (5.1 Abuse, Misuse, and Addiction; 5.2 Risks to Patients with Serious Cardiac Disease; 5.9 Motor and Verbal Tics, and Worsening of Tourette’s Syndrome), 10/2023.
Page: Desoxyn · Source: Desoxyn label (revised 09/2024)
May 2024
Focalin label revised
Current label revised 5/2024 (DailyMed SPL date May 30, 2024).
Recent Major Changes listed on the label: Boxed Warning, 10/2023; Dosage and Administration (2.1 Pretreatment Screening; 2.2 Recommended Dosage), 10/2023; Warnings and Precautions (5.1 Abuse, Misuse, and Addiction; 5.2 Risks to Patients with Serious Cardiac Disease; 5.8 Acute Angle Closure Glaucoma; 5.9 Increased Intraocular Pressure and Glaucoma; 5.10 Motor and Verbal Tics, and Worsening of Tourette’s Syndrome), 10/2023.
Page: Focalin · Source: Focalin label (revised 05/2024)
November 2023
Methylin label revised
Current label revised 11/2023 (DailyMed SPL date November 1, 2023).
Recent Major Changes listed on the label: Boxed Warning, 10/2023; Dosage and Administration (2.1 Pretreatment Screening; 2.2 General Dosing Information; 2.3 Dosage Reduction and Discontinuation), 10/2023; Warnings and Precautions (5.1 Abuse, Misuse, and Addiction; 5.2 Risks to Patients with Serious Cardiac Disease; 5.8 Acute Angle Closure Glaucoma; 5.9 Increased Intraocular Pressure and Glaucoma; 5.10 Motor and Verbal Tics, and Worsening of Tourette’s Syndrome), 10/2023.
Page: Methylin · Source: Methylin label (revised 11/2023)
June 2021
Adhansia XR label revised
Current label revised 6/2021.
The label lists no Recent Major Changes, so the specific edits were not identified for this log.
Page: Adhansia XR · Source: Adhansia XR label (revised 06/2021)
Current label versions
Revision date printed on each label, and the “Updated” date DailyMed shows for the listing (the SPL effective date), read Oct 29, 2026.
| Product | Label revised | DailyMed SPL date | Link |
|---|---|---|---|
| Concerta | 4/2026 | April 20, 2026 | label |
| Vyvanse | 4/2026 | April 30, 2026 | label |
| Adderall XR | 4/2026 | April 30, 2026 | label |
| Focalin XR | 9/2025 | September 23, 2025 | label |
| Jornay PM | 9/2025 | October 3, 2025 | label |
| Ritalin LA | 9/2025 | September 23, 2025 | label |
| Aptensio XR | 9/2025 | — | label |
| Quillivant XR | 3/2026 | March 24, 2026 | label |
| Cotempla XR-ODT | 9/2025 | March 2, 2026 | label |
| Azstarys | 9/2025 | May 11, 2026 | label |
| Daytrana | 9/2025 | September 1, 2025 | label |
| Xelstrym | 9/2025 | December 23, 2025 | label |
| Qelbree | 1/2025 | October 5, 2026 | label |
| Simtriyo | 7/2026 | July 31, 2026 | label |
| Strattera (atomoxetine) | 6/2026 | June 30, 2026 | label |
| Intuniv | 6/2025 | June 23, 2025 | label |
| Kapvay | 10/2025 | October 31, 2025 | label |
| Ritalin | 2/2025 | February 5, 2025 | label |
| Adderall | not shown | May 29, 2024 | label |
| Mydayis | 4/2026 | April 30, 2026 | label |
| Adhansia XR | 6/2021 | — | label |
| Onyda XR | 4/2025 | April 11, 2025 | label |
| QuilliChew ER | 4/2026 | April 8, 2026 | label |
| Focalin | 5/2024 | May 30, 2024 | label |
| Adzenys XR-ODT | 9/2025 | May 13, 2026 | label |
| Dyanavel XR | 9/2025 | February 24, 2026 | label |
| Evekeo | 06/2025 | October 10, 2025 | label |
| Relexxii | 9/2025 | September 26, 2025 | label |
| Metadate CD | 10/2026 | October 21, 2026 | label |
| Arynta | 12/2025 | July 30, 2025 | label |
| Zenzedi | 05/2025 | November 26, 2025 | label |
| ProCentra | 05/2025 | May 14, 2025 | label |
| Dexedrine Spansule | not shown | September 25, 2025 | label |
| Methylin | 11/2023 | November 1, 2023 | label |
| Evekeo ODT | No current DailyMed label (discontinued; page uses the Drugs@FDA label, revised 10/2023) | label | |
| Desoxyn | 9/2024 | September 30, 2024 | label |
| Atoncy | 3/2026 | April 2, 2026 | label |
| Methylphenidate ER (10/20 mg) | 10/2025 | October 8, 2025 | label |
| Methylphenidate Chewable | 3/2025 | March 12, 2025 | label |